Sarah A O'Dowd is Director of Protagonist Therapeutics, Inc. Currently has a direct ownership of 5,130 shares of PTGX, which is worth approximately $195,401. The most recent transaction as insider was on Jan 02, 2025, when has been sold 5,130 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.13K
n/a 3M change
n/a 12M change
Total Value Held $195,401

Sarah A O'Dowd Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 02 2025
BUY
Grant, award, or other acquisition
-
5,130 Added 50.0%
5,130 Common Stock

Also insider at

ICHR
ICHOR HOLDINGS, LTD. Technology
SAO

Sarah A O'Dowd

Director
Fremont, CA

Track Institutional and Insider Activities on PTGX

Follow Protagonist Therapeutics, Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTGX shares.

Notify only if

Insider Trading

Get notified when an Protagonist Therapeutics, Inc insider buys or sells PTGX shares.

Notify only if

News

Receive news related to Protagonist Therapeutics, Inc

Track Activities on PTGX